Study of Alteplase Versus Placebo Through a Pleural Catheter to Treat Symptomatic Septated Malignant Pleural Effusion

What this Trial Is About

Researchers are evaluating the use of alteplase to improve pleural fluid drainage and reduce breathlessness in patients with non-draining symptomatic septated malignant pleural effusion. Alteplase, a medicine that helps dissolve blood clots, is commonly used in conditions like heart attacks and strokes. This trial aims to see if alteplase can better manage symptoms in this specific lung condition. Participants are randomly assigned to one of two groups. One group receives alteplase instilled through an indwelling pleural catheter IPC, which is then capped for 1 to 2 hours before draining. The other group receives a placebo in the same way, with the option to receive alteplase after one week. The study assesses effects on breathlessness and drainage, with treatments delivered via the IPC. During the study, participants will have their breathlessness measured using visual scales at multiple time points including 48 hours, 1 week, 2 weeks, and every 4 weeks until the catheter is removed or death. Researchers will also monitor adverse events, quality of life, and complications. The main safety outcomes are tracked throughout the study, which may last about one year on average.

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion